(For treatment side effects and complications only)
We have a particular specialism in caring for myeloproliferative neoplasms (MPN) and chronic myeloid leukaemia (CML).
Myeloproliferative neoplasms (MPN) are types of blood cancer that are caused when the bone marrow produces either too many or not enough blood cells. Although they are officially classed as blood cancers, many people feel well and their disease is stable or progresses very slowly.
There are many different types of MPN but the classical MPNs fall into three main categories:
There are also several atypical or non-classical MPNs.
MPNs are caused by gene mutations in stem cells. We don’t know why these mutations happen in some people. Research is taking place to find out why and to look at which gene mutations are most common in different MPNs.
Symptoms vary depending on the type of MPN. Many people have no symptoms at all. People who do have symptoms may experience:
Chronic myeloid leukaemia (CML) usually develops very slowly and, for many people, it can be well controlled. Around 750 people are diagnosed each year in the UK. They can be any age although it is more common as you get older.
CML develops when the spongy material inside some bones (bone marrow) produces too many myeloid cells – immature white blood cells that are not fully developed and do not work properly. Scientists don't yet know why this happens. It doesn't seem to run in families or be linked to smoking, diet, chemicals or infections. It's more common over the age of 60 and slightly more common in men.
Many people have no symptoms in the early stages. CML is sometimes discovered when people are having blood tests for something else. If undiagnosed, it may progress and symptoms may include:
At The Clatterbridge Cancer Centre, we diagnose and treat CML and all types of MPN. Dr Nauman Butt, our lead MPN clinician, is one of the very small number of UK specialists with a particular interest in atypical MPNs such as systemic mastocytosis and hypereosinophilic syndromes.
We accept referrals for diagnosis as well as treatment and can make laboratory diagnosis from tissue samples which include blood and bone marrow. Dr Rachel Wells is Liquid Lead for haemato-oncology diagnostics.
Treatments are all offered in line with NICE guidelines. We also have an active clinical trials portfolio for MPN and CML.
We have our own on-site stem cell transplant unit for patients with complex disease.
We have a dedicated team of specialists in myeloproliferative neoplasms (MPN) and chronic myeloid leukaemia (CML).
Dr Nauman Butt, Consultant Haemato-Oncologist and Lead Clinician for MPN & CML
Nauman has a special interest in MPN and CML. He is one of only a few specialists nationally with an interest in systemic mastocytosis and hypereosinophilic syndromes. He has an active clinical trials portfolio and is a member of the NCRI's MPN Clinical Trials Subgroup. Nauman has contributed to several of the British Society for Haematology guidelines, including leading on the guidelines for the investigation and management of eosinophilia. [Read Nauman's consultant profile.]
Dr Rachel Wells, Consultant Haemato-Oncologist
Rachel has a special interest in diagnosis and treatment of MPN and CML. She trained and worked in Newcastle-upon-Tyne up until 2018 when she was given the opportunity to come and work at The Clatterbridge Cancer Centre as part of the MPN team. She is also Liquid Lead for the Haemato-Oncology Diagnostic Service in Liverpool (LCL), responsible for reporting tissue samples which include blood and bone marrow biopsies. [Read Rachel's consultant profile.}
Advanced Nurse Practitioner
Clinical Nurse Specialists
Our MPN & CML team also work closely with colleagues across The Clatterbridge Cancer Centre including the leukaemia team, the stem cell transplant team, clinical psychology and the palliative and enhanced supportive care team.